Skip to content

BridgeBio Pharma BBIO Long-Term Debt

Long-Term Debt at other companies

Pfizer logo
PfizerPFE
$60.57B+5.1%
Royalty Pharma logo
Royalty PharmaRPRX
$8.58B+29.6%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$42.15B-8.7%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$117.85M-35.0%
Biogen logo
BiogenBIIB
$6.29B+38.2%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$12.98B+119%
Enterprise value$15.36B+178%
P/S22.4×-24.1×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebt.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BridgeBio Pharma's long-term debt?
BridgeBio Pharma (BBIO) reported long-term debt of $2.65B in Q1 2026.
What is the long-term trend for BridgeBio Pharma's long-term debt?
Over 4 years (2020 to 2024), BridgeBio Pharma's long-term debt has grown at a 47.5% compound annual growth rate (CAGR), from $92.42M to $437.34M.